share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GUYER DAVID R

SEC ·  May 17 05:23
Summary by Futu AI
On May 14, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], engaged in multiple transactions involving the company's common stock. Guyer executed the sale of 11,625 shares at a price of $12.649 per share, resulting in a total market value of $147,044.63. Prior to this sale, Guyer acquired 6,525 shares at $3.26 each and an additional 3,250 shares at $3.5 each through the exercise or conversion of derivative securities. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals totaled 5,550 shares of common stock.
On May 14, 2024, David R. Guyer, associated with EyePoint Pharmaceuticals, Inc. [EYPT], engaged in multiple transactions involving the company's common stock. Guyer executed the sale of 11,625 shares at a price of $12.649 per share, resulting in a total market value of $147,044.63. Prior to this sale, Guyer acquired 6,525 shares at $3.26 each and an additional 3,250 shares at $3.5 each through the exercise or conversion of derivative securities. Following these transactions, Guyer's direct holdings in EyePoint Pharmaceuticals totaled 5,550 shares of common stock.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.